2024-10-20 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**1. Performance Comparison:**

Johnson & Johnson (JNJ) has lagged behind the S&P 500 (VOO) in terms of cumulative returns. Over the period analyzed, JNJ's cumulative return was 37.8%, while the S&P 500 achieved 137.88%. This results in a significant negative divergence of -100.08%, placing JNJ in the 4.75th percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

JNJ's closing price is $165.12.  Its price has been trending slightly upward with the following moving averages:

* 5-day moving average: $163.91
* 20-day moving average: $161.89
* 60-day moving average: $162.46

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 68.09. This indicates that JNJ is currently in the overbought territory, suggesting a potential correction may be on the horizon.
* **PPO (Percentage Price Oscillator):** 0.29. A positive PPO suggests bullish momentum, but the value is relatively low, indicating that the momentum may be weakening.
* **Delta_Previous_Relative_Divergence:** -3.92. This negative value suggests a short-term downward trend in JNJ's performance relative to the S&P 500.
* **Expected Return:** 0.0%.  This indicates that JNJ is not expected to outperform the S&P 500 in the long run, based on current data.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

JNJ's recent earnings have been relatively stable, with revenue consistently exceeding $21 billion. While the most recent earnings report is not publicly available, it is expected that JNJ will continue to deliver strong financial performance.  Analysts expect steady growth in the pharmaceutical sector and JNJ's strong position in the market suggests continued success.

**5. News and Recent Issues:**

**Recent Market Outlook:** JNJ remains a staple in many investors' portfolios, known for its dividend yield and its position as a "defensive" stock during market downturns.  However, recent concerns regarding the company's exposure to litigation and the potential impact of economic uncertainty have led to some market volatility.

**Analyst Opinions:** While some analysts remain optimistic about JNJ's long-term prospects, there are increasing concerns about the company's ability to maintain its growth trajectory. The company faces regulatory and legal challenges, which could impact its future performance.  

**Performance Highlights:**  JNJ continues to be a dividend stalwart, with a consistent dividend payout history. However, the company's recent performance has been lackluster compared to its peers and the broader market.

**6. Comprehensive Analysis:**

Johnson & Johnson (JNJ) is a large-cap, diversified healthcare conglomerate with a long history of dividend payouts. However, its recent performance has lagged behind the S&P 500. The company faces challenges related to legal issues and regulatory pressures. Although its recent earnings have been stable and it is expected to continue delivering strong financial performance, JNJ may face some near-term headwinds. The technical indicators suggest potential for a correction.  Despite a history of dividend stability, its current outlook compared to the S&P 500 does not suggest outperforming the market in the long run.

**7. Report in English:**

This report provides a comprehensive analysis of Johnson & Johnson (JNJ) stock based on publicly available data. The analysis includes performance comparison with the S&P 500, recent price movement, technical indicators, recent earnings and outlook, and news/recent issues. The report concludes that while JNJ is a stable company with a strong track record, its current performance and market outlook suggest it may face challenges in outperforming the market in the near future.  
